Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COR 101

Next Previous
Drug Profile

COR 101

Alternative Names: COR-101; STE90-C11

Latest Information Update: 15 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corat Therapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 08 Jul 2021 CORAT Therapeutics and Dermapharm Holding signs agreement for development of COR 101
  • 25 Apr 2021 Phase-I/II clinical trials in COVID-2019 infections in Germany (IV) (NCT04674566)
  • 16 Mar 2021 The central ethics committee recommends approval to conduct the clinical phase Ib/II trial of COR 101 for COVID-2019 infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top